74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Ipsen SA.
Closed
Sector Finance
110.3 1.1
Overview
Share price change
24h
Min
110.1
Max
110.3
Income | 232M |
|---|---|
Sales | -1.2B 585M |
P/E Sector Avg | 25.785 26.698 |
Dividend yield | 1.07 |
Profit margin | 13.244 |
EBITDA | -399M 83M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +13.22 upside |
Dividend yield Sector Avg | 1.07% 3.82% |
|---|
Market Cap | 9.1B |
|---|---|
Previous open | 109.2 |
Previous close | 110.3 |
News Sentiment
By Acuity
30%
70%
102 / 545 Finance
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Ipsen SA. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ipsen SA. Forecast
Price Target
By TipRanks
13.22% upside
12 Months Forecast
Average 125 EUR 13.22%
High 145 EUR
Low 110 EUR
Based on 7 Wall Street analysts offering 12 month price targets forIpsen SA. - Dist in the last 3 months.
Sentiment
By Acuity
102 / 545 Finance
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ipsen SA.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
